Back to Search
Start Over
The activation of RARα prevents surgery-induced cognitive impairments via the inhibition of neuroinflammation and the restoration of synaptic proteins in elderly mice.
- Source :
-
International immunopharmacology [Int Immunopharmacol] 2024 Mar 30; Vol. 130, pp. 111772. Date of Electronic Publication: 2024 Mar 02. - Publication Year :
- 2024
-
Abstract
- Post-operative cognitive dysfunction (POCD) is a multi-etiological symptom mainly occurred in elderly people after surgery. The activation of retinoic acid receptor α (RARα), a transcriptional factor, was previously predicated to be negatively associated with the occurrence of POCD. However, the mechanisms underlying anti-POCD effects of RARα were still unclear. In this study, AM580, a selective agonist of RARα, and all-trans-retinoic acid (ATRA), a pan agonist of RAR, significantly alleviated cognitive dysfunction and increased the expression of RARα in elderly mice after surgery, which was decreased by RO41-5253, an antagonist of RARα. A bioinformatic study further predicted that the activation of RARα might produce anti-POCD effects via the restoration of synaptic proteins. Both agonists inhibited the expression of Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (Myd88) and the phosphorylation of nuclear factorkappa-B (NF-κB), leading to the prevention of microglial over-activation and pro-inflammatory cytokines secretion in the hippocampal regions of elderly mice after surgery. Moreover, AM580 and ATRA increased the expression of brain-derived neurotrophic factor (BDNF) and postsynaptic density protein 95 (PSD95), and the phosphorylation of extracellular signal-regulated kinase (ERK) and cAMP-response element binding protein (CREB). All these results suggested that the activation of RARα prevented surgery-induced cognitive impairments via the inhibition of neuroinflammation by the reduction of the TLR4/Myd88/NF-κB pathway and the restoration of synaptic proteins by the activation of the BDNF/ERK/CREB pathway, providing a further support that RARα could be developed as a therapeutic target for POCD.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
Mice
Brain-Derived Neurotrophic Factor metabolism
Extracellular Signal-Regulated MAP Kinases metabolism
Mice, Inbred ICR
Myeloid Differentiation Factor 88 metabolism
Neuroinflammatory Diseases prevention & control
Signal Transduction
Toll-Like Receptor 4 metabolism
Tretinoin pharmacology
Benzoates pharmacology
Benzoates therapeutic use
NF-kappa B metabolism
Postoperative Cognitive Complications prevention & control
Retinoic Acid Receptor alpha agonists
Tetrahydronaphthalenes pharmacology
Tetrahydronaphthalenes therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1705
- Volume :
- 130
- Database :
- MEDLINE
- Journal :
- International immunopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38432148
- Full Text :
- https://doi.org/10.1016/j.intimp.2024.111772